The US Food and Drug Administration (FDA) has approved the first generics of Xarelto (rivaroxaban), a cardio vascular drug developed by Germany’s Bayer (BAYN: DE) and marketed in the USA by Johnson & Johnson (NYSE: JNJ).
Awarded to Taro Pharmaceuticals Industries, a subsidiary of Indian generics major Sun Pharma (BSE: 524715), this generic approval is targeted to reduce the risk of major cardiovascular events in adult patients with coronary artery disease (CAD) and the risk of major thrombotic vascular events in adult patients with peripheral artery disease (PAD), including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD.
Bayer recorded 2024 global sales for Xarelto of 3.48 billion euros ($3.78 billion).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze